167 related articles for article (PubMed ID: 17697829)
1. Evidence for the continued safety and tolerability of fixed-dose isosorbide dinitrate/hydralazine in patients with chronic heart failure (the extension to African-American Heart Failure Trial).
Yancy CW; Ghali JK; Braman VM; Sabolinski ML; Worcel M; Archambault WT; Franciosa JA
Am J Cardiol; 2007 Aug; 100(4):684-9. PubMed ID: 17697829
[TBL] [Abstract][Full Text] [Related]
2. Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial.
Taylor AL; Ziesche S; Yancy CW; Carson P; Ferdinand K; Taylor M; Adams K; Olukotun AY; Ofili E; Tam SW; Sabolinski ML; Worcel M; Cohn JN;
Circulation; 2007 Apr; 115(13):1747-53. PubMed ID: 17372175
[TBL] [Abstract][Full Text] [Related]
3. Effect of fixed-dose combination of isosorbide dinitrate and hydralazine on all hospitalizations and on 30-day readmission rates in patients with heart failure: results from the African-American Heart Failure Trial.
Anand IS; Win S; Rector TS; Cohn JN; Taylor AL
Circ Heart Fail; 2014 Sep; 7(5):759-65. PubMed ID: 24970468
[TBL] [Abstract][Full Text] [Related]
4. Atrial fibrillation and mortality in African American patients with heart failure: results from the African American Heart Failure Trial (A-HeFT).
Mitchell JE; Tam SW; Trivedi K; Taylor AL; O'Neal W; Cohn JN; Worcel M
Am Heart J; 2011 Jul; 162(1):154-9. PubMed ID: 21742102
[TBL] [Abstract][Full Text] [Related]
5. A review of isosorbide dinitrate and hydralazine in the management of heart failure in black patients, with a focus on a new fixed-dose combination.
Cheng JW
Clin Ther; 2006 May; 28(5):666-78. PubMed ID: 16861089
[TBL] [Abstract][Full Text] [Related]
6. Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial.
Ghali JK; Tam SW; Ferdinand KC; Lindenfeld J; Sabolinski ML; Taylor AL; Worcel M; Curry CL; Cohn JN;
Am J Cardiovasc Drugs; 2007; 7(5):373-80. PubMed ID: 18041162
[TBL] [Abstract][Full Text] [Related]
7. Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT.
Cohn JN; Tam SW; Anand IS; Taylor AL; Sabolinski ML; Worcel M;
J Card Fail; 2007 Jun; 13(5):331-9. PubMed ID: 17602978
[TBL] [Abstract][Full Text] [Related]
8. Effects of nitrates and hydralazine in heart failure: clinical evidence before the african american heart failure trial.
Elkayam U; Bitar F
Am J Cardiol; 2005 Oct; 96(7B):37i-43i. PubMed ID: 16226934
[TBL] [Abstract][Full Text] [Related]
9. Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American Heart Failure Trial.
Ferdinand KC; Elkayam U; Mancini D; Ofili E; Piña I; Anand I; Feldman AM; McNamara D; Leggett C
Am J Cardiol; 2014 Jul; 114(1):151-9. PubMed ID: 24846808
[TBL] [Abstract][Full Text] [Related]
10. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.
Cohn JN; Johnson G; Ziesche S; Cobb F; Francis G; Tristani F; Smith R; Dunkman WB; Loeb H; Wong M
N Engl J Med; 1991 Aug; 325(5):303-10. PubMed ID: 2057035
[TBL] [Abstract][Full Text] [Related]
11. The African American Heart Failure Trial: a clinical trial update.
Taylor AL
Am J Cardiol; 2005 Oct; 96(7B):44-8. PubMed ID: 16226935
[TBL] [Abstract][Full Text] [Related]
12. Fixed-Dose Versus Off-Label Combination of Isosorbide Dinitrate Plus Hydralazine Hydrochloride: Retrospective Propensity-Matched Analysis in Black Medicare Patients with Heart Failure.
Ofili E; Anand I; Williams RA; Akinboboye O; Xu L; Puckrein G
Adv Ther; 2017 Aug; 34(8):1976-1988. PubMed ID: 28707284
[TBL] [Abstract][Full Text] [Related]
13. Effect of fixed-dose combined isosorbide dinitrate/hydralazine in elderly patients in the African-American heart failure trial.
Taylor AL; Sabolinski ML; Tam SW; Ziesche S; Ghali JK; Archambault WT; Worcel M; Cohn JN;
J Card Fail; 2012 Aug; 18(8):600-6. PubMed ID: 22858074
[TBL] [Abstract][Full Text] [Related]
14. Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox.
Tam SW; Sabolinski ML; Worcel M; Packer M; Cohn JN
Clin Pharmacokinet; 2007; 46(10):885-95. PubMed ID: 17854237
[TBL] [Abstract][Full Text] [Related]
15. Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate in African-American Patients With Heart Failure.
Ziaeian B; Fonarow GC; Heidenreich PA
JACC Heart Fail; 2017 Sep; 5(9):632-639. PubMed ID: 28711446
[TBL] [Abstract][Full Text] [Related]
16. Isosorbide dinitrate-hydralazine improves outcomes in African Americans with heart failure.
Colvin-Adams M; Taylor AL
Cleve Clin J Med; 2007 Mar; 74(3):227-34. PubMed ID: 17375804
[TBL] [Abstract][Full Text] [Related]
17. The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (Met-HeFT).
Wiggers H; Køber L; Gislason G; Schou M; Poulsen MK; Vraa S; Nielsen OW; Bruun NE; Nørrelund H; Hollingdal M; Barasa A; Bøttcher M; Dodt K; Hansen VB; Nielsen G; Knudsen AS; Lomholdt J; Mikkelsen KV; Jonczy B; Brønnum-Schou J; Poenaru MP; Abdulla J; Raymond I; Mahboubi K; Sillesen K; Serup-Hansen K; Madsen JS; Kristensen SL; Larsen AH; Bøtker HE; Torp-Petersen C; Eiskjær H; Møller J; Hassager C; Steffensen FH; Bibby BM; Refsgaard J; Høfsten DE; Mellemkjær S; Gustafsson F
Am Heart J; 2021 Jan; 231():137-146. PubMed ID: 33039340
[TBL] [Abstract][Full Text] [Related]
18. The African-American Heart Failure Trial: background, rationale and significance.
Taylor AL; Cohn JN; Worcel M; Franciosa JA;
J Natl Med Assoc; 2002 Sep; 94(9):762-9. PubMed ID: 12392039
[TBL] [Abstract][Full Text] [Related]
19. Exploring the potential synergistic action of spironolactone on nitric oxide-enhancing therapy: insights from the African-American Heart Failure Trial.
Ghali JK; Tam SW; Sabolinski ML; Taylor AL; Lindenfeld J; Cohn JN; Worcel M
J Card Fail; 2008 Nov; 14(9):718-23. PubMed ID: 18995175
[TBL] [Abstract][Full Text] [Related]
20. G-protein beta-3 subunit genotype predicts enhanced benefit of fixed-dose isosorbide dinitrate and hydralazine: results of A-HeFT.
McNamara DM; Taylor AL; Tam SW; Worcel M; Yancy CW; Hanley-Yanez K; Cohn JN; Feldman AM
JACC Heart Fail; 2014 Dec; 2(6):551-7. PubMed ID: 25306451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
